ixazomib,daratumumab
takeda,janssen
['ixazomib', 'mmsm']
joining the #asco22 myeloma session this morning! follow along in the thread for the latest #mmsm abstracts! first, ifm study of ixazomib + dara without dex in elderly/frail. median age 82, all r/r, 36% with hrmm. 60% discontinued. 56% &gt;gr 3 aes. 1-yr pfs 70%. #gerionc 
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????